About
Revolo Biotherapeutics develops peptide-based immunomodulatory therapies that restore immune homeostasis to treat allergic and autoimmune diseases, with lead candidates in clinical development for conditions such as eosinophilic esophagitis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis.
Explore Revolo Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.